Yellow fever and the risk of this disease in travellers;Het risico van gele koorts voor reizigers

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 33, 2006, Pages 1815-1820

  Roukens, A H E ^a   Visser, L G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

AFRICA; BLEEDING TENDENCY; CLINICAL FEATURE; DISEASE TRANSMISSION; ENCEPHALITIS; EPIDEMIC; FLAVIVIRUS; HEART FAILURE; HUMAN; IMMUNE DEFICIENCY; INFECTION; JAUNDICE; KIDNEY FAILURE; MOSQUITO; PRIMATE; REVIEW; SOUTH AFRICA; TRAVEL; VACCINATION; VIRUS REPLICATION; VIRUS STRAIN; YELLOW FEVER;

ANIMALS; CULICIDAE; DISEASE OUTBREAKS; HUMANS; INSECT BITES AND STINGS; INSECT VECTORS; RISK FACTORS; TRAVEL; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 33749170956     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kager PA. Virale hemorragische koorts. Ned Tijdschr Geneeskd. 1998;142:448-52.
2. Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: Saunders; 1999. p. 815-79.
3. Kerr JA. The clinical aspects and diagnosis of yellow fever. In: Strode GK, editor. Yellow fever. New York: McGraw-Hill; 1951. p. 385-426.
4. Augustin G. History of yellow fever. New Orleans: Searcy & Pfaff; 1909.
5. Carter HR. Yellow fever. An epidemiological and historical study of its place of origin. Baltimore: Williams & Wilkins; 1931.
6. Chang GJ, Cropp BC, Kinney RM, Trent DW, Gubler DJ. Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus. J Virol. 1995;69:5773-80.
7. Lepiniec L, Dalgarno L, Huong VT, Monath TP, Digoutte JP, Deubel V. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol. 1994;75(Pt 2):417-23.
8. Wang E, Weaver SC, Shope RE, Tesh RB, Watts DM, Barrett AD. Genetic variation in yellow fever virus: duplication in the 3′ noncoding region of strains from Africa. Virology. 1996;225:274-81.
9. Reed W, Agramonte A. Landmark article. Feb 16, 1901. The etiology of yellow fever. An additional note. By Walter Reed, Jas. Carroll and Aristides Agramonte. JAMA. 1983;250:649-58.
10. Germain M, Cornet M, Mouchet J, Herve JP, Robert V, Camicas JL, et al. [Sylvatic yellow fever in Africa recent advances and present approach (author's transl)]. Med Trop (Mars). 1981;41:31-43.
11. Aitken TH, Tesh RB, Beaty BJ, Rosen L. Transovarial transmission of yellow fever virus by mosquitoes (Aedes aegypti). Am J Trop Med Hyg. 1979;28:119-21.
12. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis. 2004; 27:319-30.
13. Monath CP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34:1369-78.
14. Colebunders R, Mariage JL, Coche JC, Pirenne B, Kempinaire S, Hantson P, et al. A Belgian traveler who acquired yellow fever in the Gambia. Clin Infect Dis. 2002;35:e113-6.
15. Smith HH, Theiler M. The adaptation of unmodified strains of yellow fever virus to cultivation in vitro. J Exp Med. 1937;65:801-8.
16. Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med. 1937;65:767-86.
17. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 170 yellow fever vaccine. Bull World Health Organ. 1981;59:895-900.
18. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85:131-4.
19. Barwick Eidex R. History of thymoma and yellow fever vaccination. The Yellow Fever Vaccine Safety Working Group. Lancet. 2004;364:936.
20. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. The Yellow Fever Vaccine Safety Working Group. Vaccine. 2005;23:3256-63.
21. Smithburn KC, Durieux C, Koerber C, Penna HA, Dick GW, Courtois G, et al. Post-vaccination reactions. In: Yellow fever vaccination. Geneve: WHO; 1956. p. 178-81.
22. Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51:1-11.
23. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001;7:945-51.
24. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98-104.
25. Jennings AD, Gibson CA, Miller BR, Mathews JH, Mitchell CJ, Roehrig JT, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis. 1994;169:512-8.
26. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol. 1999;103:698-701.
27. Cobelens FG. Gele koorts-vaccinatie en zwangerschap. Ned Tijdschr Geneeskd. 1994;138:920.
28. Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Campinas Group on Yellow Fever Immunization during pregnancy. Vaccine. 2006;24:1421-6.